ArticleNature biotechnology2025
Lipid nanoparticle-mediated mRNA delivery to CD34
Abstract read
In one paragraph
Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Towards mRNA therapeutics 2.0.Nature reviews. Drug discovery · 2026Review
- Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease.Cell stem cell · 2026Article
- Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy.Nature communications · 2026Article
- Non-invasive nanoparticle barcoding in nonhuman primates.Nature biotechnology · 2026Article
- Engineered lipid nanoparticles for in vivo and durable editing of haematopoietic stem cells within humanized mice.Nature biomedical engineering · 2026Article
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.Materials today. Bio · 2026Review
- The Nucleolus in Human Disease: Ribosome Biogenesis, Nucleolar Surveillance, and Therapeutic Opportunities.Biomolecules · 2026Review
- Two Classes of Protein Therapeutics: Why Dose-Response Architecture Defines the Boundary of mRNA Medicines.Pharmaceutics · 2026Review
- Towards clinical translation of nanomedicines: Formulation scale-up and model systems.Advanced drug delivery reviews · 2026Review
- Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives.MedComm · 2026Review
- Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets.MedComm · 2026Review
- Galactosylated LNP-mediated hepatic Sam68 silencing improves glucose homeostasis in diabetes by suppressing gluconeogenesis.Journal of nanobiotechnology · 2026Article
- Lipid nanoparticle screening in nonhuman primates with minimal loss of life.Nature biotechnology · 2026Article
- mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.MedComm · 2026Review
- Lipid nanoparticles for bone marrow-targeted RNA therapeutics.Journal of nanobiotechnology · 2026Review
- CAR-CD34 (+) hematopoietic stem/progenitor cells produced in vivo protect against thoracic aortic aneurysm and dissection.Nature communications · 2026Article
- Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.bioRxiv : the preprint server for biology · 2026Article
- Clinical Significance of IKBKB Mutations:Saudi medical journal · 2026Review
- Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond.Cell reports. Medicine · 2026Review
- Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells.Advanced materials (Deerfield Beach, Fla.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Hyejin Kim *Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7937-2733
Ryan Zenhausern *Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2538-0033
Kara GentryWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Liming LianWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Sebastian G HuayamaresWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-2859-3074
Afsane RadmandPetit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
David LoughreyWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Ananda R PodilapuWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Marine Z C HatitWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Huanzhen NiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Andrea LiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Aram ShajiiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Hannah E PeckWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Keyi HanWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5141-1673
Xuanwen HuaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5946-0808
Shu JiaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-6854-7537
Michele MartinezCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Charles LeeCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Philip J SantangeloWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Alice TarantalCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
James E DahlmanWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA. james.dahlman@emory.edu.ORCID http://orcid.org/0000-0001-7580-436X
Funding
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5MImplementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1MSCGE Comparative Studies SupplementU42OD027094 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J., SEGAL, DAVID J · 2019 to 2023
$14.2MAtlanta Network for Training In KUH Scientific Research (ATLANTIS)TL1DK136047 · NIDDK · EMORY UNIVERSITY · PI Vivien Andrea Sheehan · 2022 to 2026
$3.0MHighly Specific ZFN-Based HSC Gene Editing Therapies Identified By In Vivo Barcode Nanoparticle Screens And Rationally Designed MrnaUG3TR002855 · NCATS · GEORGIA INSTITUTE OF TECHNOLOGY · PI DAHLMAN, JAMES, SANTANGELO, PHILIP J · 2019 to 2021
$2.2MHighly Specific ZFN-Based HSC Gene Editing Therapies Identified By In Vivo Barcode Nanoparticle Screens And Rationally Designed MrnaUH3TR002855 · NCATS · EMORY UNIVERSITY · PI DAHLMAN, JAMES · 2022 to 2023
$1.3MFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) P51-OD011107Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) TL1DK136047Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) UH3-TR002855NCATS NIH HHS UG3 TR002855NCATS NIH HHS UH3 TR002855NCATS NIH HHS UL1 TR002378NIDDK NIH HHS TL1 DK136047NIH HHS P51 OD011107NIH HHS U42 OD027094ODCDC CDC HHS U42 OD027094
Abstract
Transplantation of ex vivo engineered hematopoietic stem cells (HSCs) can lead to robust clinical responses but carries risks of adverse events from bone marrow mobilization, chemotherapy conditioning and other factors. HSCs have been modified in vivo using lipid nanoparticles (LNPs) decorated with targeting moieties, which increases manufacturing complexity. Here we screen 105 LNPs without targeting ligands for effective homing to the bone marrow in mouse. We report an LNP named LNP
Indexed as
Antigens, CD34Hematopoietic Stem CellsLipidsNanoparticlesRNA, MessengerAnimalsHematopoietic Stem Cell TransplantationHumansLiposomesMacaca mulattaMiceAntigens, CD34Lipid NanoparticlesLipidsLiposomesRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.